Humanigen Inc

Humanigen — Investor Presentation (January 2021)

33 slides from Humanigen's investor presentation, Jan 11, 2021

  1. Slide 1: Humanigen

    Humanigen January 2021 Humanigen

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    2 Cautionary Note Regarding Forward - Looking Statements All statements other than statements of historical facts contained in this presentation, including information concerning our po ssible or assumed future results of operations and expenses, business strategies and plans, competitive position,

  3. Slide 3: Company Highlights

    3 Company Highlights Leading expertise in Hyper - inflammation and Cytokine Storm across multiple therapeutic applications Strong mid - to - late stage clinical pipeline including potential registration studies in CAR - T (US) and GvHD (UK); collaboration with Kite/Gilead in CAR - T 515+ patient Pha

  4. Slide 4: Lenzilumab: reduce risk of progression to IMV and/or death

    4 Reduce risk of progression to IMV and/or death Lenzilumab, a dual action monoclonal antibody, which safely replenishes T - Cells and dampens the harmful inflammatory response, can be administered intravenously over a single day, to newly hospitalized and hypoxic COVID - 19 patients, who may or may

  5. Slide 5: Clinical-Stage Pipeline

    5 Clinical?Stage PipelineIndication Phase Status Centers Partners Lenzilumab Potential Registration Enabling Prevention / treatment of Hyper-inflammation / Cytokine Storm 3 Recruiting 515+ patients 475+ 24+ US 11 Brazil Company sponsored ACTIV-5/BET Prevention / treatment of Hyper-inflammation / Cyt

  6. Slide 6: Accomplishments and Objectives

    6 Accomplishments and Objectives □ Phase 3 full enrollment and topline data □ ACTIV - 5 topline data □ Application for Emergency Use Authorization □ Commercial distribution under EUA if granted □ BLA submission □ ZUMA - 19 Phase 1b CAR - T data □ Initiate GvHD study with IMPACT Group x Mayo case - c

  7. Slide 7: Therapeutic for Patients: Market Potential/Financial overview

    7 3 2 1 Therapeutic for COVID - 19 Patients Prevention / Treatment of Acute GvHD Market Potential/Financial overview

  8. Slide 8: Neutralization of GM-CSF to Prevent Cytokine Storm

    8 Neutralization of GM - CSF to Prevent COVID - 19 Cytokine Storm  GM - CSF neutralization prevents CD14+CD16+ inflammatory myeloid cell activation and reduces all downstream monokine production  IL - 6 blockade reduces only IL - 6 and does not block inflammatory myeloid cells activation and all d

  9. Slide 9: Lenzilumab Phase 3 in Severe or Critical COVID-19

    9 Lenzilumab Phase 3 in Severe or Critical COVID?19 Multicenter, randomized, double-blind, placebo-controlled pivotal trial NCT 04351152 Adults ? 18 yrs Hospitalized, confirmed SARS-CoV-2, COVID-19 pneumonia SpO2 ? 94% and pre IMV (N = 515+, 1:1) Lenzilumab 600mg IV Q8h x 3 on Day 1600mg IV Q8h x 3

  10. Slide 10: Mayo Clinic Case-Control Trial Design

    10 Mayo Clinic Case - Control Trial Design • Case - control study ( n=39) • 12 patients treated with lenzilumab • Lenzilumab treated patients dosed with 600 mg intravenously for three doses • Contemporaneous standard of care control patients selected from electronic medical records from across Mayo

  11. Slide 11: Mayo Clinic Case-Control Trial Baseline Characteristics

    11 Mayo Clinic Case - Control Trial Baseline Characteristics Table 1. Demographics and baseline characteristics Characteristic Lenzilumab group (n=12) Control group (n=27) P-value Age, y 65 (52-70) 68 (61-76) .25 Male 8 (67%) 19 (70%) > .99 Female 4 (33%) 8 (30%) > .99 Race White 9 (75%) 17 (63%) .7

  12. Slide 12: Lenzilumab Significantly Improved Clinical Outcomes

    12 Lenzilumab Significantly Improved Clinical Outcomes 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 V e n t i l a t o r - F r e e S u r v i v a l ( % ) Days Post Treatment Lenzilumab Control χ 2 = 3.67, P= .06 Figure 1 A B 0% 10% 20% 30% 40% 50% 60% 70%

  13. Slide 13: Lenzilumab Phase 3 Interim Analysis

    13 Lenzilumab Phase 3 - Interim Analysis * Benefit that is in addition to any benefit from steroids and/or remdesivir in the control arm • Patient characteristics for first 165 patients show good distribution of: • Disease severity • Age • Diversity • Extensive use of concomitant therapies • Estimat

  14. Slide 14: ACTIV-5/BET Big Effect Trial

    14 ACTIV - 5/BET Big Effect Trial (BET - B) for the Treatment of COVID - 19 • Lenzilumab is the third of six agents selected by NIH, the only GM - CSF molecule selected • Over 400 compounds reviewed by NIH for inclusion in ACTIV protocols • Humanigen is the only small company in NIH - sponsored stud

  15. Slide 15: Improving efficacy / safety of CAR-T

    15 3 2 1 Therapeutic for COVID - 19 Patients Improving efficacy / safety of CAR - T Prevention / Treatment of Acute GvHD 4 Market Potential/Financial overview

  16. Slide 16: ZUMA-19 Potential Registration Study

    16 ZUMA - 19 Potential Registration Study Efficacy Safety Dosing Schedule • 3+3 Design to find recommended phase 2 dose • Cohort 1 with Starting Dose • Cohort 2 with Escalating Dose Clinical Trial Design Phase 1b Phase 2 ▪ At Recommended Dose • Complete Response (CR) • Partial Response (PR) • Object

  17. Slide 17: Prevention / Treatment of Acute GvHD

    17 3 2 1 Therapeutic for COVID - 19 Patients Improving efficacy / safety of CAR - T Prevention / Treatment of Acute GvHD 4 Market Potential/Financial overview

  18. Slide 18: IMPACT Partnership/HGEN GvHD Trial Design

    18 IMPACT Partnership/HGEN GvHD Trial Design Dosing Schedule (every 2 weeks) N= 240 Patients Clinical Trial Design 6 Months Allo Transplant Ongoing follow - up for safety and efficacy Lenzilumab + SOC Day 28 Day 0 GvHD Dx MAGIC biomarker (<48 hours post Dx) Intermediate + High Risk (AA2+AA3) Randomi

  19. Slide 19: Market Potential / Financial overview

    19 4 2 1 Therapeutic for COVID - 19 Patients Improving efficacy / safety of CAR - T Market Potential / Financial overview 3 Prevention / Treatment of Acute GvHD

  20. Slide 20: Lenz Commercial Preparation Underway

    20 Lenz Commercial Preparation Underway Humanigen is positioned for commercial success in 2021 and beyond. 1 Anticipated lenzilumab EUA in 1H2021 and BLA filing in 2H2021 2 Unique MOA addressing an unmet need in the quest for effective COVID?19 treatments 3 $1B opportunity estimated for lenzilumab i

  21. Slide 21: Disease Landscape

    21 1. Johns Hopkins Coronavirus Resource Center 2. Total Hospitalizations ÷ Total Cases (COVID Tracking Project / Johns Hopkins Coronavirus Resource Center) 3. Fair Health Report as reported in Healthcare Finance News (November 5, 2020) 4. ACTT - 2 355,000+ US COVID Deaths 1 21 Million+ US COVID Cas

  22. Slide 22: Sizeable and Sustainable Market Opportunity

    22 Anticipating a Greater Number of Hospitalizations in 2021 Hospitalizations Will Remain Through 2022 and Beyond 2020 2021 2022 and Beyond 600K+ Hospitalizations Despite a vaccine, hospitalizations will increase Despite herd immunity and widespread vaccinations, hospitalizations remain COVID - 19 H

  23. Slide 23: Continued Need for New Therapeutics Even with Vaccines

    23 1. Eli Lilly Press Release: December 15, 2020 2. Regeneron Press Release: November 21, 2020 3. H.C. Wainwright, Joseph Pantginis, Ph.D.: December 3, 2020 “2021 revenue is expected to be between $26.5 billion and $28.0 billion, driven by … an estimated $1 billion to $2 billion of revenue from COVI

  24. Slide 24: Disease Progression

    24 Viral Acute R esponse Cytokine Storm Disease Onset » COVID - 19 can cause uncontrolled inflammatory responses — aka the “Cytokine Storm” — characterized by marked pro - inflammatory cytokine release in patients » These SARS - CoV - 2 - induced immune abnormalities may lead to respiratory failure,

  25. Slide 25: Significant Therapeutic Need for Hospitalized and Hypoxic Patients

    25 Hyperinflammatory Phase Pulmonary/Inflammatory Phase Early Infection Phase 1 2 3 Patient Journey Outpatient Symptom Management COVID - 19 Diagnosis In Hospital Outpatient Invasive Mechanical Ventilation Present to Hospital with Hypoxia (SpO2<94% on Room Air) Low Flow or High Flow Supplemental O2

  26. Slide 26: Key Stakeholders

    26 Understand the needs of hospitalized COVID - 19 patients and support them in their treatment Help physicians understand the value lenzilumab can contribute to better patient outcomes Work with hospital systems and key institutions to ensure patients get timely access to treatment To bring lenzilu

  27. Slide 27: Patient Perspectives

    27 The Median Hospital length of stay for survivors is 10 – 13 days 1 COVID - 19 symptoms can linger for months with long - term effects on the lungs, heart and brain 2 Cost of hospital care can be significant and exceed $150K per patient 3 The emotional toll hospitalizations place on patients and t

  28. Slide 28: Target Physicians

    28 Pulmonologists 12,000 9,000 13,500 Pulmonologists Infectious Disease Physicians Critical Care Physicians Infectious Disease Physicians , Pulmonologists , and Critical Care Physicians Oversee Treatment Decisions for Hospitalized COVID - 19 Patients ~34.5K COVID Specialists 1. PUD Source: NCBI – HH

  29. Slide 29: The Burden of COVID-19 Will Continue

    29 The Burden of COVID - 19 Will Continue • Hospitals and staff are overwhelmed • Targeted HCPs are eager to reduce COVID - 19 hospitalizations and discharge patients sooner • Despite vaccines, HCPs do not anticipate COVID - 19 hospitalizations disappearing Current Therapies Are Inadequate • Remdesi

  30. Slide 30: Hospital Access and Reimbursement Landscape

    30 • COVID - 19 patients can be hospitalized for a week or more , possibly in the ICU • Cost of care is estimated at ~$13K per day for a hospitalized patient • Inpatient COVID - 19 drug therapies are currently covered by Medicare Part A Given the current market needs and lenzilumab’s unique product

  31. Slide 31: Go-To-Market Partner: Eversana

    31 To help bring lenzilumab to market, we are partnering with an end - to - end commercial partner — Eversana. Go - To - Market Partner An end - to - end commercial partner provides ultimate flexibility, allowing us to quickly scale for a successful launch if EUA is granted Rationale For Selecting E

  32. Slide 32: Financial Overview

    32 Financial Overview Balance at December 31, 2020 (M)* • Cash and cash equivalents $68 • Shares outstanding 55 Uplisting to NASDAQ Achieved on September 18, 2020 *balances are unaudited

  33. Slide 33: Upcoming Catalysts and Goals

    33 Upcoming Catalysts and Goals Complete recruitment in Phase 3 COVID - 19 study and ACTIV - 5 EUA submission and subsequent approval Topline data from Phase 3 study Prepare for EUA distribution and scale - up manufacturing, BLA Continue CAR - T recruitment and initiate GvHD study 1 3 2 4 5

Humanigen — Investor Presentation (January 2021) on 6ix